Enhanced CMC infrastructure at Cranbury site aims to improve bioavailability, streamline formulation development and support faster progression of challenging drug candidates into clinical trials
Preclinical CRO strengthens leadership team with key executive appointments as it scales its human tissue-based drug discovery platform
Deal brings late-stage lung cancer candidates zidesamtinib and neladalkib into GSK’s portfolio
The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities
The facility integrates advanced scientific infrastructure and specialised workflows to support complex drug delivery systems, sterile injectables, and differentiated dosage forms
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
The company also confirmed that ABS-1230 has been accepted into the U.S. Food and Drug Administration’s Rare Disease Evidence Principles (RDEP) process
Subscribe To Our Newsletter & Stay Updated
